Abstract:Background: Drug-induced liver injury (DILI) is gradually becoming a common global problem that causes acute liver failure, especially in acute hepatic damage caused by acetaminophen (APAP). Paeoniflorin (PF) has a wide range of therapeutic effects to alleviate a variety of hepatic diseases. However, the relationship between them is still poorly investigated in current studies. Purpose: This work aimed to explore the protective effects of PF on APAP-induced hepatic damage and researched the potential molecular mechanisms. Methods: C57BL/6J male mice were injected with APAP to establish DILI model and were given PF for five consecutive days for treatment. Aiming to clarify the pharmacological effects, the molecular mechanisms of PF in APAP-induced DILI was elucidated by high-throughput and other techniques. Results: The results demonstrated that serum levels of ALP, γ-GT, AST, TBIL, and ALT were decreased in APAP mice by the preventive effects of PF. Moreover, PF notably alleviated hepatic tissue inflammation and edema. Meanwhile, the results of TUNEL staining and related apoptotic factors coincided with the results of transcriptomics, suggesting that PF inhibited hepatocyte apoptosis by regulated MAPK signaling. Besides, PF also acted on reactive oxygen species (ROS) to regulate the oxidative stress for recovery the damaged mitochondria. More importantly, transmission electron microscopy showed the generation of autophagosomes after PF treatment, and PF was also downregulated mTOR and upregulated the expression of autophagy markers such as ATG5, ATG7, and BECN1 at the mRNA level and LC3, p62, ATG5, and ATG7 at the protein level, implying that the process by which PF exerted its effects was accompanied by the occurrence of autophagy. In addition, combinined with molecular dynamics simulations and western blotting of MAPK, the results suggested p38 as a direct target for PF on APAP. Specifically, PF-activated autophagy through the downregulation of MAPK/mTOR signaling, which in turn reduced APAP injury. Conclusions: Paeoniflorin mitigated liver injury by activating autophagy to suppress oxidative stress and apoptosis via the MAPK/mTOR signaling pathway. Taken together, our findings elucidate the role and mechanism of paeoniflorin in DILI, which is expected to provide a new therapeutic strategy for the development of paeoniflorin.

Fluorofenidone protects against acute liver failure in mice by regulating MKK4/JNK pathway

The Antihepatic Fibrotic Effects of Fluorofenidone Via Mapk Signalling Pathways

Mefunidone ameliorates acute liver failure in mice by inhibiting MKK4-JNK pathway

Fluorofenidone Attenuates Hepatic Fibrosis By Suppressing The Proliferation And Activation Of Hepatic Stellate Cells

Protective Effect of Fluorofenidone Against Acute Lung Injury Through Suppressing the MAPK/NF-B Pathway

Protective Effect of Fluorofenidone Against Acute Lung Injury Through Suppressing the MAPK/NF-κB Pathway

The Inhibition of Bruton Tyrosine Kinase Alleviates Acute Liver Failure via Downregulation of NLRP3 Inflammasome.

Fluorofenidone Protects Liver Against Inflammation and Fibrosis by Blocking the Activation of NF‐κB Pathway

Fluorofenidone Ameliorates Cholestasis and Fibrosis by Inhibiting Hepatic Erk/-Egr-1 Signaling and Tgfβ1/Smad Pathway in Mice.

Fluorofenidone attenuates renal fibrosis by inhibiting the mtROS-NLRP3 pathway in a murine model of folic acid nephropathy

Fluorofenidone Attenuates Renal Interstitial Fibrosis by Enhancing Autophagy and Retaining Mitochondrial Function

Fluorofenidone Protects Mice from Lethal Endotoxemia Through the Inhibition of TNF-α and IL-1β Release

Fluorofenidone Protects Against Acute Kidney Injury.

Tectorigenin Protects Against Experimental Fulminant Hepatic Failure by Regulating the TLR4/mitogen‐activated Protein Kinase and TLR4/nuclear Factor‐κb Pathways and Autophagy

Fluorofenidone Affects Hepatic Stellate Cell Activation in Hepatic Fibrosis by Targeting the TGF-β1/Smad and MAPK Signaling Pathways.

Bifidobacterium Longum R0175 Protects Mice Against APAP-induced Liver Injury by Modulating the Nrf2 Pathway.

Fluorofenidone is an Effective Drug for Cholestasis and Fibrosis in a Preclinical Study

Fluorofenidone Alleviates Renal Fibrosis by Inhibiting Necroptosis Through RIPK3/MLKL Pathway

AGK2 Pre-Treatment Protects Against Thioacetamide-Induced Acute Liver Failure Via Regulating the MFN2-PERK Axis and Ferroptosis Signaling Pathway.

Paeoniflorin protects hepatocytes from APAP-induced damage through launching autophagy via the MAPK/mTOR signaling pathway

Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin‑mediated NLRP3 inflammasome activation